59510
Methanesulfonic acid
suitable for HPLC, LiChropur™, ≥99.5% (T)
조직 및 계약 가격을 보려면 로그인를 클릭합니다.
크기 선택
보기 변경
제품정보 (DICE 배송 시 비용 별도)
Linear Formula:
CH3SO3H
CAS 번호:
Molecular Weight:
96.11
UNSPSC Code:
12161700
NACRES:
NB.21
PubChem Substance ID:
EC Number:
200-898-6
Beilstein/REAXYS Number:
1446024
MDL number:
Quality Level
vapor density
3.3 (vs air)
vapor pressure
1 mmHg ( 20 °C)
assay
≥99.5% (T)
form
liquid
quality
LiChropur™
technique(s)
HPLC: suitable
color
APHA: ≤35
refractive index
n20/D 1.428-1.430, n20/D 1.429 (lit.)
bp
167 °C/10 mmHg (lit.)
mp
17-19 °C (lit.)
density
1.481 g/mL at 25 °C (lit.)
suitability
corresponds to standard for HPLC
SMILES string
O=S(O)(C)=O
InChI
1S/CH4O3S/c1-5(2,3)4/h1H3,(H,2,3,4)
InChI key
AFVFQIVMOAPDHO-UHFFFAOYSA-N
Packaging
Clear borosilicate glass, high hydrolytic resistance (Type I)
Analysis Note
test by UV spectroscopy corresponds to requirements
Legal Information
LiChropur is a trademark of Merck KGaA, Darmstadt, Germany
signalword
Danger
Hazard Classifications
Acute Tox. 4 Dermal - Acute Tox. 4 Oral - Eye Dam. 1 - Met. Corr. 1 - Skin Corr. 1B - STOT SE 3
target_organs
Respiratory system
저장 등급
8A - Combustible corrosive hazardous materials
wgk
WGK 1
flash_point_f
372.2 °F - closed cup
flash_point_c
189 °C - closed cup
Mohammad M Fares et al.
Biomaterials science, 6(11), 2938-2950 (2018-09-25)
The design of new hydrogel-based biomaterials with tunable physical and biological properties is essential for the advancement of applications related to tissue engineering and regenerative medicine. For instance, interpenetrating polymer network (IPN) and semi-IPN hydrogels have been widely explored to
Adnan H Mahmood et al.
International journal of pharmaceutics, 481(1-2), 71-78 (2015-02-01)
To introduce better antibiotics for the treatment of some infectious diseases in sheep and to expand the range of antibiotics available for veterinary medicine, pharmacokinetics of two antibiotics marbofloxacin (MBX) and trovafloxacin (TVX) were investigated in sheep after intramuscular injection.
Chris Twelves et al.
Breast cancer research and treatment, 148(3), 553-561 (2014-11-09)
Data from two phase 3 studies of eribulin were pooled in analyses initially requested by the European Medicines Agency to assess whether specific patient subgroups, previously treated with an anthracycline and a taxane, benefited from eribulin. Study 305/EMBRACE included women